Stay updated on ICON: Immunogenic Chemo + Ipilimumab/Nivolumab Clinical Trial

Sign up to get notified when there's something new on the ICON: Immunogenic Chemo + Ipilimumab/Nivolumab Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ICON: Immunogenic Chemo + Ipilimumab/Nivolumab Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to a Phase IIb study evaluating immunogenic chemotherapy combined with Ipilimumab and Nivolumab in patients with metastatic hormone receptor positive breast cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:31:52.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.' This change provides a more detailed explanation of what eligibility criteria entail for clinical research participation.
    Difference
    54%
    Check dated 2024-05-22T21:14:34.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:26:50.000Z thumbnail image

Stay in the know with updates to ICON: Immunogenic Chemo + Ipilimumab/Nivolumab Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ICON: Immunogenic Chemo + Ipilimumab/Nivolumab Clinical Trial page.